Showing results (351-360 of 451) with videos related to

Sort By:
Pageof 46
Stroke|August 1, 2013
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialDavid Preiss, Thomas D Giles, Laine E Thomas, et al.
Stroke|August 11, 2016
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 TrialsKennedy R Lees, Jonathan Emberson, Lisa Blackwell, et al.
BMJ Open|October 5, 2021
Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort studyManisha Nair, Shakuntala Chhabra, Saswati Sanyal Choudhury, et al.
Thrombosis and Haemostasis|March 9, 2016
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart DiseaseRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
The Lancet. Global Health|May 19, 2018
Adiposity and risk of ischaemic and haemorrhagic stroke in 0·5 million Chinese men and women: a prospective cohort studyZhengming Chen, Andri Iona, Sarah Parish, et al.
Circulation. Genomic and Precision Medicine|August 29, 2019
Physical Activity, Sedentary Leisure Time, Circulating Metabolic Markers, and Risk of Major Vascular DiseasesYuanjie Pang, Christiana Kartsonaki, Huaidong Du, et al.
Hypertension (Dallas, Tex. : 1979)|January 5, 2023
Genetically Predicted Differences in Systolic Blood Pressure and Risk of Cardiovascular and Noncardiovascular Diseases: A Mendelian Randomization Study in Chinese AdultsRobert Clarke, Neil Wright, Robin Walters, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
European Journal of Heart Failure|March 11, 2015
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fractionSøren L Kristensen, Pardeep S Jhund, Lars Køber, et al.
Circulation|January 6, 2017
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)Søren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Pageof 46